Date |
Company |
Amount |
Funding type |
Investors |
Therapeutic area |
Type of Information |
2017-05-02 |
ImCheck Therapeutics (France) |
€20 million |
series A financing round |
Boehringer Ingelheim Venture Fund (BIVF) (Germany) Kurma Partners (France) Idinvest (France) Gimv (Belfium) LSP (The Netherlands) |
Cancer - Oncology - Immunological diseases |
Series A financing round |
2017-05-02 |
Exocobio (Republic of Korea) |
$11 million |
series A financing round |
SBI Investment (Republic of Korea) Atinum Investment (Republic of Korea) ID Ventures (Republic of Korea) Dt&Investment (USA - PA) |
Autoimmune diseases - Dermatological diseases |
Series A financing round |
2017-04-28 |
Agios Pharmaceuticals (USA - MA) |
$287 million |
private placement |
|
Cancer - Oncology - Genetic diseases - Metabolic diseases |
Private placement |
2017-04-26 |
RegenXBio (USA - MD) |
$87.2 million |
private placement |
|
Rare diseases - Genetic diseases |
Private placement |
2017-04-24 |
Oryzon Genomics (Spain) |
$300,000 |
grant |
Alzheimer’s Drug Discovery Foundation (ADDF) (USA - NY) |
Neurodegenerative diseases |
Grant |
2017-04-21 |
Galapagos (Belgium) |
€363.9 million |
capital increase |
|
|
Capital increase |
2017-04-19 |
Synpromics (UK) |
£5.2 million |
financing round |
Calculus Capital (UK) Scottish Investment Bank (UK) private shareholders |
Technology - Services |
Financing round |
2017-04-17 |
Arena Pharmaceuticals (USA - CA) |
$79.4 million |
private placement |
|
|
Private placement |
2017-04-13 |
Delmar Pharmaceuticals (USA - CA) |
$ 9 million |
private placement |
|
Cancer - Oncology |
Restructuring |
2017-04-12 |
Polyphor (Switzerland) |
CHF 40 million (€ 37.43 million) |
private placement |
Varuma (Switzerland) Ingro Finanz (Switzerland) |
Infectious diseases |
Private placement |
2017-04-10 |
Adaptimmune (UK) |
$42 million |
private placement |
Matrix Capital (USA - MA) |
Cancer - Oncology |
Private placement |
2017-04-04 |
Novosanis (Belgium) |
€ 200 000 |
grant |
Interreg CrossCare (Belgium) |
Infectious diseases - Diagnostic |
Grant |
2017-04-04 |
Repositive (UK) |
£2.5 million (€ 2.92 million) |
series A financing round |
Ananda Social Venture Fund (Germany) Force Over Mass Capital (UK) Amadeus Capital Partners (UK) Jonathan Milner |
Technology - Services |
Fundraising |
2017-04-03 |
Mereo BioPharma (UK) |
£15.0 million |
private placement |
|
Rare diseases - Genetic diseases |
Private placement |
2017-03-31 |
Osmia Pharmaceuticals (Sweden) |
SEK 42 million (€ 4.4 million) |
private placement |
|
Cancer - Oncology - Veterinary medicine |
Private placement |
2017-03-31 |
Aveo Pharmaceuticals (USA - MA) |
$15.0 Million |
private placement |
|
|
Private placement |
2017-03-30 |
Cidara Therapeutics (USA - CA) |
$6.9 million |
grant |
CARB-X (Combating Antibiotic Resistant Bacteria Accelerator) (USA) |
Infectious diseases |
Grant |
2017-03-30 |
Tango Therapeutics (USA - MA) |
$55 million |
series A financing round |
Third Rock Ventures (USA - MA) |
Cancer - Oncology |
Fundraising |
2017-03-30 |
Forge Therapeutics (USA - CA) |
$8.8 million |
grant |
CARB-X (Combating Antibiotic Resistant Bacteria Accelerator) (USA) |
|
Grant |
2017-03-28 |
Nosopharm (France) |
€2.4 million |
financing round |
Auriga Partners (France) Kreaxi (France) Alto Invest (France) |
Infectious diseases |
Capital increase |